Cargando…
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
Cladribine (CLAD) is a purine nucleoside analog approved in tablet form to treat highly active multiple sclerosis (MS). CLAD tablets are the first oral therapy with an infrequent dosing schedule, administered in two annual treatment courses, each divided into two treatment cycles comprising 4–5 days...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026047/ https://www.ncbi.nlm.nih.gov/pubmed/35451662 http://dx.doi.org/10.1007/s10354-022-00931-4 |